Sp373
IS IT DYSPEPSIA OR GASTROPARESIS CASE PRESENTATION
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis. LIVE STREAM SESSION
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis. LIVE STREAM SESSION
Presenter
Houston Methodist Hospital
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Challenging Cases: Managing Common Gastrointestinal Sensorimotor Disorders
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
